Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: The Innohep® in Renal Insufficiency Study (IRIS)

Thrombosis Research

Volumn 128, Issue 1, 2011, Pages 27-34

  Leizorovicz, Alain ^a   Siguret, Virginie ^a   Mottier, Dominique ^a  

^a NONE

Author keywords

DVT; Elderly; Heparin; Renal insufficiency; Tinzaparin

Indexed keywords

ANTIVITAMIN K; HEPARIN; TINZAPARIN;

ACUTE DEEP VEIN THROMBOSIS; AGED; ARTICLE; BLEEDING; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HEART FAILURE; HUMAN; INFECTION; KIDNEY DYSFUNCTION; LEG; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; RENAL INSUFFICIENCY; VENOUS THROMBOSIS;

EID: 79958022690     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.03.002     Document Type: Article

References (25)

1. Rosendaal FR, Van Hylckama Vlieg A, Doggen CJ. Venous thrombosis in the elderly. J Thromb Haemost 2007;5(Suppl 1):310-7. (Pubitemid 46958848)
2. Oger E. Incidence of venous thromboembolism: a community based study in western France. Thromb Haemost 2000;83:657-60. (Pubitemid 30248509)
3. Lopez-Jimenez L,MonteroM, Gonzalez-Fajardo J, et al. Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE). Haematologica 2006;91:1046-51. (Pubitemid 44204770)
4. Vasco B, Villalba JC, Lopez-Jimenez L, et al. Venous Thromboembolism in nonagenarians. Findings from the RIETE Registry. Thromb Haemost 2009;101:1112-8.
5. Piazza G, Seddighzadeh A, Goldhaber SZ. Deep-vein thrombosis in the elderly. Clin Appl Thromb Hemost 2008;14:393-8.
6. Monreal M, Falgá C, Valle R, et al. RIETE Investigators. Venous thromboembolism in patients with renal insufficiency: findings from the RIETE Registry. Am J Med 2006;119:1073-9. (Pubitemid 44834366)
7. van Dongen CJ, van den Belt G, Prins MH, Lensing AW. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2004;4:CD001100.
8. Pautas E, Gouin I, Bellot O, et al. Safety profile of tinzaparin administered at a standard curative dose in two hundred very elderly patients. Drug Saf 2002;25:725-33. (Pubitemid 34983375)
9. Montalescot G, Collet JP, Tanguy ML, et al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 2004;110:392-8. (Pubitemid 38993847)
10. Hirsh J, Bauer KA, Donati MB, et al. Parenteral Anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edn). Chest 2008;133:141S-59S.
11. Lim W, Dentali F, Eikelboom JW, et al. Meta-analysis: LMWH and bleeding in patients with Severe Renal Insufficiency. Ann Intern Med 2006;144:673-84. (Pubitemid 46780653)
12. Dinwoodey DL, Ansell JE. Heparins, low-molecular-weight heparins, and pentasaccharides: use in the older patient. Cardiol Clin 2008;26:145-55. (Pubitemid 351491575)
13. Gouin-Thibault I, Siguret V, Pautas E. A need for evidence-based clinical practice guidelines for the use of heparins in the elderly. Clin Interv Aging 2010;5:119-21.
14. Siguret V, Pautas E, Février M, et al. Elderly patients treated with tinzaparin (innohep®) administered once daily (175 Anti-Xa IU/kg): Anti-Xa and anti-IIa activities over 10 days. Thromb Haemost 2000;84:800-4.
15. Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindication to the use of low molecular weight heparin? Arch Intern Med 2002;162:2605-9.
16. Mahe I, Aghassarian M, Drouet L, et al. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical patients with impaired renal function. Thromb Haemost 2007;97:581-6.
17. Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692-4.
18. Hull R, Raskob G, Pineo G, et al. Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med 1992;326:975-82.
19. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. N Engl J Med 1997;337:663-9. (Pubitemid 27375472)
20. Spencer FA, Gore JM, Lessard D, et al. Venous thromboembolism in the elderly - a community based perspective. Thromb Haemost 2008;100:780-8.
21. Falga C, Capdevila JA, Soler S, et al. Clinical outcome of patients with venous thromboembolism and renal insufficiency. Thromb Haemost 2007;98:771-6. (Pubitemid 47555068)
22. Data on file, LEO Pharma, Denmark; 2010.
23. Heit JA, Silverstein MD, Mohr DN, et al. Predictors of survival after deep vein thrombosis and pulmonary embolism. Arch Intern Med 1999;159:445-53. (Pubitemid 29108909)
24. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.
25. Chronic Kidney Disease Prognosis Consortium; Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375:2073-81.